MelioOne®
The first non-contraceptive
IUD for Period Pain

Period pain needs innovation

  • 1.8 billion people in the world have periods 

  • 1.4 billion suffer from period pain every month 

  • 38% of menstruating women experience period pain so severely they're forced out of activities of daily living 

Meliodays is a pharmaceutical company focused on transforming women’s health with an innovative IUD for period pain. We are currently in the prototype development phase and on track to proceed with pre-clinical trials by the fourth quarter this year. 

  • Investor Capacura GmbH
  • Investor FS LifeScience Investment GmbH
  • Investor Heimat Boost
  • Investor OHA Beteiligungs GmbH
  • Partner SpinLab Accelerator
  • Medical Forge logo
  • Partner OHA Accelerator

No hormones.
No cycle disruption.
Minimal systemic
side-effects.

MelioOne® is the first non-hormonal, non-contraceptive IUD for period pain. Through an innovative slow-release mechanism, the IUD administers a prolonged low dose of pain medication over one year to manage inflammation at its source and prevent period pain from happening. The dosage is equivalent to 1 painkiller tablet, such as Ibuprofen 400. 

Development timeline showing various planned milestones for Meliodays' non-contraceptive IUD, MelioOne up to 2029

While the development timeline reflects the rigor typical of pharmaceutical innovation, MelioOne® is classified as a combination product—incorporating both a medical device and a pharmacological agent. This dual classification means MelioOne® is held to the highest regulatory standards, providing a strong foundation for trust and long-term safety once it reaches the market.

Abstract illustration of overlapping profiles in various colors on a pink background to portray the gender health gap

The gender health gap is real—and nowhere is it more visible than in period pain. Menstrual health continues to be one of the least prioritized and underfunded areas in medical research. Despite affecting up to 91% of women globally, dysmenorrhea or period pain remains underdiagnosed, undertreated, and widely normalized.

This neglect carries not only personal consequences, but economic and social costs—from missed education and productivity to reduced workplace participation. At Meliodays, we believe pain is not normal and that women deserve better. Our work begins with menstruation—but it's about so much more: closing the gender health gap, one innovation at a time. 

Latest News, Product Developments and Corporate Updates

20.03.2025